BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals

   BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron

PR Newswire

SAN DIEGO, Oct. 26, 2012

SAN DIEGO, Oct. 26, 2012 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR)
today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has leased
an additional 80,500 square feet of space at The Landmark at Eastview campus
in Tarrytown, New York comprised of approximately 46,000 square feet of space
in the 777 Building and approximately 34,500 square feet of space in the 765

Named as the world's top biopharmaceutical employer in a recent Science
magazine survey, as well as one of the 20 best places to work in the U.S.
science industry by The Scientist magazine, Regeneron will use the new
research and development laboratories for its research into treatments for
ophthalmology, cancer, inflammation, hypercholesterolemia, and other
conditions. Regeneron markets three products in the United States: EYLEA^®
(aflibercept) Injection, ZALTRAP^® (ziv-aflibercept) Injection for Intravenous
Infusion, and ARCALYST^® (rilonacept) Injection for Subcutaneous Use. ZALTRAP
is co-commercialized with Sanofi.

According to Alan D. Gold, Chairman and Chief Executive Officer of BioMed
Realty, "Our singular focus is to create optimal environments that support
transformational research and groundbreaking science. Our eight-year
relationship with Regeneron, one of the truly inspiring stories in the life
science industry, exemplifies this commitment. We salute our friends at
Regeneron on their successful launch of EYLEA, the recent launch of ZALTRAP,
and the groundbreaking research being performed every day at The Landmark.
With their latest expansion, we look forward to supporting their success for
many years to come."

The Landmark at Eastview is one of the largest privately-owned, multi-tenant
science parks in New York State. The campus consists of eight buildings and
over 1.1 million rentable square feet of research and development facilities
and high-tech office space.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.1
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research. Additional
information is available at

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company'target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

SOURCE BioMed Realty

Contact: Rick Howe, Senior Director, Corporate Communications,
Press spacebar to pause and continue. Press esc to stop.